ArticleNeuro-oncology2010
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Article in Neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 105 citations in OpenAlex.
- Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.World neurosurgery · 2018Trial
- Limitations of Gliadel Wafers and Strategies for Next-Generation Local Delivery Systems for Glioblastoma.Cancers · 2026Review
- Development of a high-grade glioma preclinical surgery model using an inducible KRAS/TP53 Oncopig.Frontiers in oncology · 2026Article
- Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors.Journal for immunotherapy of cancer · 2025Article
- Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.Journal of neuro-oncology · 2025Article
- The value of case reports.Frontiers in veterinary science · 2025Article
- The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.Journal of neuro-oncology · 2024Article
- The CCL2-CCR4 Axis Promotes Regulatory T Cell Trafficking to Canine Glioma Tissues.Research square · 2024Article
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors.Cancers · 2024Article
- Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas.Life (Basel, Switzerland) · 2023Review
- Tumor microenvironment in a minipig model of spinal cord glioma.Journal of translational medicine · 2023Article
- Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials.Cancers · 2023Review
- Chemotherapy for the treatment of intracranial glioma in dogs.Frontiers in veterinary science · 2023Review
- Diffusion tensor imaging tractography in the one-humped camel (Frontiers in veterinary science · 2023Article
- Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses.Cancer research communications · 2022Article
- Comparison of linear and volumetric criteria for the determination of therapeutic response in dogs with intracranial gliomas.Journal of veterinary internal medicine · 2022Article
- Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue.Pharmaceutics · 2022Review
- Advancements in drug delivery methods for the treatment of brain disease.Frontiers in veterinary science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Canine spontaneous intracranial tumors bear striking similarities to their human tumor counterparts and have the potential to provide a large animal model system for more realistic validation of novel therapies typically developed in small rodent models. We used spontaneously occurring canine gliomas to investigate the use of convection-enhanced delivery (CED) of liposomal nanoparticles, containing topoisomerase inhibitor CPT-11. To facilitate visualization of intratumoral infusions by real-time magnetic resonance imaging (MRI), we included identically formulated liposomes loaded with Gadoteridol. Real-time MRI defined distribution of infusate within both tumor and normal brain tissues. The most important limiting factor for volume of distribution within tumor tissue was the leakage of infusate into ventricular or subarachnoid spaces. Decreased tumor volume, tumor necrosis, and modulation of tumor phenotype correlated with volume of distribution of infusate (Vd), infusion location, and leakage as determined by real-time MRI and histopathology. This study demonstrates the potential for canine spontaneous gliomas as a model system for the validation and development of novel therapeutic strategies for human brain tumors. Data obtained from infusions monitored in real time in a large, spontaneous tumor may provide information, allowing more accurate prediction and optimization of infusion parameters. Variability in Vd between tumors strongly suggests that real-time imaging should be an essential component of CED therapeutic trials to allow minimization of inappropriate infusions and accurate assessment of clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.